Core One Labs Aktie WKN: A2P8K3 ISIN: CA21872J2083

Börse
Lang & Schwarz

Kurs zur Core One Labs Aktie

0,40 EUR

0,00 % 0,00 EUR

Login

Kursdaten

Geld (Stk.) 0,400 (5.000)
Brief (Stk.) 0,400 (5.000)
Spread 0,000
Geh. Stück 500 Stk
Eröffnung 0,400
Vortag 0,400
52 Wochen Hoch 1,100
52 Wochen Tief 0,082

Stand: 02.09.2020 - 10:16:22 Uhr

k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.

k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Kursdaten: k.A.

k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Kursdaten: k.A.

k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Kursdaten: k.A.

k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Kursdaten: k.A.

k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Kursdaten: k.A.

k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Kursdaten: k.A.

k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Kursdaten: k.A.

Anzeige
Smartbroker
Sparplan Aktion: Besparen Sie Aktien auf Smartbroker.de

Hauptdiskussion (21)

Neu laden

Alle Kommentare Neu laden

I
Ingos vom 15.09.20 22:17 Uhr

Gibt es schon wieder einen Handel?

Moonhawk
Moonhawk vom 06.09.20 10:26 Uhr

https://www.futurezone.de/science/article229165854/Coronavirus-Medikamen-Cannabis-So-koennte-die-Droge-wirken.html?utm_medium=Social&utm_campaign=echobox&utm_source=Facebook#Echobox=1599236426

J
JoeKob vom 27.08.20 20:23 Uhr

http://crweworld.com/article/news-provided-by-accesswire/1667949/core-one-labs-announces-revocation-of-cease-trade-order

R
Räuberhotzenplotzzz vom 26.08.20 16:02 Uhr

Core One Labs completes audit, starts review of ops 2020-08-26 06:02 ET - News Release Mr. Joel Shacker reports CORE ONE LABS PROVIDES SHAREHOLDER UPDATE Core One Labs Inc. has provided shareholders with an update on its continuing operational developments. The company was recently able to raise $4-million in a private placement in order to recapitalize the company and finance operations. After the company was financed it was able to complete acquisitions involving Rejuva Alternative Medicine Research Centre Inc. and Shahcor Health Services Inc. that will allow the company to expand its operation to focus on new applications for its current proprietary technology. As a result of travel restrictions arising from the continuing global pandemic the company was unable to complete the necessary on-site work at its California facility, required to finish the 2019 audit within the required time frame. The company has now completed audit, resumed trading and has commenced a review of operations to determine areas for improvement. During this transition period, management, led by newly appointed chief executive officer Joel Shacker, has identified many areas in which operations can be improved and require restructuring. The restructuring efforts are focused on providing the company with significant cost savings in many departments and allowing management to focus on initiatives that will drive top-line revenue. The company will continue to focus its efforts on novel drug delivery methods that address depression, anxiety, posttraumatic stress disorder, as well as substance and alcohol disorders. According to Data Bridge Market Research, the market size annually for the above conditions is in the billions of dollars. This represents a significant opportunity for the company to incorporate its patented drug delivery system for multiple novel drugs. Mr. Shacker has a history of building significant revenue generating companies. His most recent success was Thoughtful Brands where to date it has raised over $10-million and in 2019 did more than $29-million in revenue on EBITA (earnings before interest, taxes and amortization) of over 10 per cent. Mr. Shacker is joined by Ryan Hoggan who is currently the chief executive officer of Thoughtful Brands and a founder of Unified Funding LLC. The company currently owns patents on a nanostrip delivery system that provides users with an efficient and non-invasive method of delivering naturally occurring active compounds that gives them comfort in knowing they will be receiving a consistent and accurate microdose. The company currently uses the nanostrip delivery system for delivering naturally occurring compounds found in cannabis such as THC (tetrahydrocannabinol) and CBD (cannabidiol); however, it plans to start using the delivery system for other naturally occurring compounds. Currently, there is nothing in the marketplace that provides a highly effective, accurate, patient-friendly dosing such as nanostrips. "I am very excited about the changes this company is making as it will result in increased efficiency, and will refocus the business on a path aimed at driving revenues and profitability. The company has the opportunity to capitalize on an emerging market, where it will have first mover advantage to monetize a state-of-the-art proprietary delivery system. Becoming a leader in this space will allow the company to capture market share in addiction treatment, as well as treatments for anxiety and depression, creating both short- and long-term shareholder value," stated Joel Shacker, chief executive officer of the company.

R
Räuberhotzenplotzzz vom 26.08.20 16:02 Uhr

https://www.stockwatch.com/News/Item?bid=Z-C%3aCOOL-2953950&symbol=COOL&region=C

Pomp25
Pomp25 vom 26.08.20 15:42 Uhr

Ist die firma tot? Kein handel mehr

M
Martin_Steinich vom 25.08.20 20:53 Uhr

Die sind in 4 Monaten pleite. Das steht da drin. Brad lässt es sich auf den Bahamas mit eurer Kohle gut gehen 😅

R
Räuberhotzenplotzzz vom 25.08.20 02:29 Uhr

https://webfiles.thecse.com/sedar_filings/00031206/2008241124102839.pdf

Alle Kommentare Neu laden

Geld/Brief Kurse

Börse Geld Brief Zeit Volumen Kurs
Berlin 0,00 0,00 1594737642 14.07.20 0 0,47 EUR
München 0,00 0,00 1594733467 14.07.20 0 0,48 EUR
Lang & Schwarz 0,40 0,40 1599034582 02.09.20 500 0,40 EUR
CSE 0,00 0,00 1594757099 14.07.20 179.802 0,73 CAD

Realtime / Verzögert

Core One Labs

Börsennotierung

Marktkapitalisierung
6,29 Mio EUR
Anzahl der Aktien
16,04 Mio Stück

Grundlegende Daten zur Core One Labs Aktie

Finanzdaten 2016 2017 2018 2019 2020 2021
Ergebnis je Aktie (bereinigt) - - - - - -
Cashflow - - - - - -
Eigenkapitalquote - - - - - -
Verschuldungsgrad - - - - - -
Eigenkapitalrendite - - - - - -
Gesamtkapitalrendite - - - - - -
EBITDA - - - - - -
EBIT - - - - - -
Fundamentaldaten 2016 2017 2018 2019 2020 2021
Dividendenrendite - - - - - -
Kurs-Gewinn-Verhältnis (KGV) - - - - - -
Dividende je Aktie - - - - - -
Bilanzdaten 2016 2017 2018 2019 2020 2021
Netto-Provisionsüberschuss - - - - - -
Umsatzerlöse - - - - - -
Ergebnis vor Steuern - - - - - -
Steuern - - - - - -
Ausschüttungssumme - - - - - -
Nettoverzinsung - - - - - -
Zinsertrag - - - - - -
Gesamtertrag - - - - - -